A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging

Aging

Volumn 5, Issue 6, 2013, Pages 412-426

  Anvar, Seyed Yahya ^a,c   Raz, Yotam ^a,c   Verwey, Nisha ^a,c   Van der Sluijs, Barbara ^b,c   Venema, Andrea ^a,c   Goeman, Jelle J ^a,c   Vissing, John ^c,d   Van der Maarel, Silvère M ^a,c   't Hoen, Peter A C ^a,c   van Engelen, Baziel G M ^b,c   Raz, Vered ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d Rigshospitalet   (Denmark)

Author keywords

Age related diseases; Centenarians; Extreme phenotypes; TCF7L2; Type 2 diabetes

Indexed keywords

EID: 84880628916     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100567     Document Type: Article

References (48)

1. Ross CA and Poirier MA. What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol. 2005; 6:891-898.
2. Bence NF, Sampat RM and Kopito RR. Impairment of the Ubiquitin-Proteasome System by Protein Aggregation. Science. 2001; 292:1552-1555.
3. Dennissen FJA, Kholod N and van Leeuwen FW. The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim Progress in Neurobiology. 2012; 96:190-207.
4. Shao J and Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Human molecular genetics. 2007; 16 Spec No. 2:R115-123.
5. Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Current neurology and neuroscience reports. 2009; 9:76-82.
6. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nature genetics. 1998; 18:164-167.
7. Tome FM and Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta neuropathologica. 1980; 49:85-87.
8. Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E and Carmo-Fonseca M. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Human molecular genetics. 2000; 9:2321-2328.
9. Berciano MT, Villagra NT, Ojeda JL, Navascues J, Gomes A, Lafarga M and Carmo-Fonseca M. Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Human molecular genetics. 2004; 13:829-838.
10. Raz V, Routledge S, Venema A, Buijze H, van der Wal E, Anvar S, Straasheijm KR, Klooster R, Antoniou M and van der Maarel SM. Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein. Am J Pathol. 2011; 179:1988-2000.
11. Davies JE, Sarkar S and Rubinsztein DC. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Human molecular genetics. 2008; 17:1097-1108.
12. Bhattacharjee RB, Zannat T and Bag J. Expression of the polyalanine expansion mutant of nuclear poly(A)-binding protein induces apoptosis via the p53 pathway. Cell Biology International. 2012; 36:697-704.
13. Raz V, Abraham T, van Zwet EW, Dirks RW, Tanke HJ and van der Maarel SM. Reversible aggregation of PABPN1 pre-inclusion structures. Nucleus. 2011; 2:208-218.
14. Anvar SY, t Hoen PA, Venema A, van der Sluijs B, van Engelen B, Snoeck M, Vissing J, Trollet C, Dickson G, Chartier A, Simonelig M, van Ommen GJ, van der Maarel SM, et al. Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skeletal muscle. 2011; 1:15.
15. Trollet C, Anvar SY, Venema A, Hargreaves IP, Foster K, Vignaud A, Ferry A, Negroni E, Hourde C, Baraibar MA, t Hoen PA, Davies JE, Rubinsztein DC, et al. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Human molecular genetics. 2010; 19:2191-2207.
16. Chartier A, Benoit B and Simonelig M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. The EMBO journal. 2006; 25:2253-2262.
17. Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, Brais B, Rouleau GA, Parker JA and Neri C. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Human molecular genetics. 2008; 17:2108-2117.
18. Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH and Pavlath GK. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Human molecular genetics. 2010; 19:1058-1065.
19. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG and Rubinsztein DC. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nature medicine. 2005; 11:672-677.
20. Mankodi A, Wheeler TM, Shetty R, Salceies KM, Becher MW and Thornton CA. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy. Neurobiol Dis. 2012; 45:539-546.
21. Van Der Sluijs BM, Hoefsloot LH, Padberg GW, Van Der Maarel SM and Van Engelen BG. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. Journal of neurology. 2003; 250:1307-1312.
22. Welle S, Brooks AI, Delehanty JM, Needler N, Bhatt K, Shah B and Thornton CA. Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Experimental gerontology. 2004; 39:369-377.
23. Tollervey JR, Wang Z, Hortobágyi T, Witten JT, Zarnack K, Kayikci M, Clark TA, Schweitzer AC, Rot G, Curk T, Zupan B, Rogelj B, Shaw CE, et al. Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome research. 2011; 21:1572-1582.
24. Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G and Kors JA. Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome biology. 2008; 9:12.
25. de Magalhaes JP, Budovsky A, Lehmann G, Costa J, Li Y, Fraifeld V and Church GM. The Human Ageing Genomic Resources: online databases and tools for biogerontologists. Aging cell. 2009; 8:65-72.
26. Jelier R, t Hoen PA, Sterrenburg E, den Dunnen JT, van Ommen GJ, Kors JA and Mons B. Literature-aided meta-analysis of microarray data: a compendium study on muscle development and disease. BMC bioinformatics. 2008; 9:291.
27. Welle S, Brooks AI, Delehanty JM, Needler N and Thornton CA. Gene expression profile of aging in human muscle. Physiological genomics. 2003; 14:149-159.
28. Marzani B, Felzani G, Bellomo RG, Vecchiet J and Marzatico F. Human muscle aging: ROS-mediated alterations in rectus abdominis and vastus lateralis muscles. Exp Gerontol. 2005; 40:959-965.
29. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD and Kirkland JL. Fat tissue, aging, and cellular senescence. Aging Cell. 2010; 9:667-684.
30. Horan MP, Pichaud N and Ballard JWO. Review: Quantifying Mitochondrial Dysfunction in Complex Diseases of Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2012; 67:1022-1035.
31. Shigenaga MK, Hagen TM and Ames BN. Oxidative damage and mitochondrial decay in aging. Proceedings of the National Academy of Sciences. 1994; 91:10771-10778.
32. Shin DM, Kucia M and Ratajczak MZ. Nuclear and chromatin reorganization during cell senescence and aging -a mini-review. Gerontology. 2011; 57:76-84.
33. Wolfe KJ and Cyr DM. Amyloid in neurodegenerative diseases: friend or foe Semin Cell Dev Biol. 2011; 22:476-481.
34. Kuhn U, Gundel M, Knoth A, Kerwitz Y, Rudel S and Wahle E. Poly(A) tail length is controlled by the nuclear poly(A)-binding protein regulating the interaction between poly(A) polymerase and the cleavage and polyadenylation specificity factor. The Journal of biological chemistry. 2009; 284:22803-22814.
35. ohn U, Menzies FM, Vrielink JAFO, Bos AJ, Drost J, Rooijers K, Rubinsztein DC and Agami R. The Poly(A)-Binding Protein Nuclear 1 Suppresses Alternative Cleavage and Polyadenylation Sites. Cell. 2012; 149:538-553.
36. de Klerk E, Venema A, Anvar SY, Goeman JJ, Hu O, den Dunnen JT, van der Maarel Sr M, Raz V and Äòt Hoen PAC. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic acids research. 2012.
37. Simonelig M. PABPN1 shuts down alternative poly(A) sites. Cell Res. 2012; 221419-1421.
38. Meshorer E and Soreq H. Pre-mRNA splicing modulations in senescence. Aging cell. 2002; 1:10-16.
39. Van Der Sluijs BM, Hoefsloot LH, Padberg GW, Van Der Maarel SM and Van Engelen BG. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. Journal of neurology. 2003; 250:1307-1312.
40. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:12.
41. Goeman JJ, van de Geer SA, de Kort F and van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004; 20:93-99.
42. Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R and Lempicki RA. Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics. 2009; 13:11.
43. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ and von Mering C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research. 2011; 39(Database issue):2.
44. Zhu CH, Mouly V, Cooper RN, Mamchaoui K, Bigot A, Shay JW, Di Santo JP, Butler-Browne GS and Wright WE. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging cell. 2007; 6:515-523.
45. Raz V, Carlotti F, Vermolen BJ, van der Poel E, Sloos WC, Knaan-Shanzer S, de Vries AA, Hoeben RC, Young IT, Tanke HJ, Garini Y and Dirks RW. Changes in lamina structure are followed by spatial reorganization of heterochromatic regions in caspase-8-activated human mesenchymal stem cells. Journal of cell science. 2006; 119:4247-4256.
46. Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen G-JB, van der Maarel SrM and Verrips CT. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly(A)-binding protein with a single-domain intracellular antibody. Human molecular genetics. 2006; 15:105-111.
47. Greenspan P, Mayer EP and Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985; 100:965-973.
48. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD and Chen LB. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proceedings of the National Academy of Sciences. 1991; 88:3671-3675.